GLP-2 Signaling: The Gut-Growth Hormone Behind Short Bowel Therapies

GLP-1 gets most of the attention for its role in appetite and blood sugar, but it has a lesser-known sibling cut from the same precursor: GLP-2. Where GLP-1 acts largely on metabolism, GLP-2 acts on the gut itself — making the intestinal lining grow, repair, and absorb more. That single property is the basis of an entire class of drugs for short bowel syndrome.

Where GLP-2 comes from

Both GLP-1 and GLP-2 are produced from the same parent molecule, proglucagon, which is processed differently in different tissues. In the intestinal L-cells — enteroendocrine cells concentrated in the lower small intestine and colon — proglucagon is cleaved to release both GLP-1 and GLP-2 together in response to food, particularly fats and carbohydrates reaching the gut.

So after a meal, L-cells co-secrete GLP-1 (which curbs appetite and improves insulin response) and GLP-2 (which nourishes and maintains the gut lining). They are partners released by the same signal, with complementary jobs.

What the GLP-2 receptor does

GLP-2 acts through the GLP-2 receptor (GLP-2R), a G-protein-coupled receptor expressed in the intestine — on enteroendocrine cells, subepithelial myofibroblasts, and enteric neurons rather than directly on the absorptive cells. Because of this indirect arrangement, GLP-2's growth effects are mediated substantially through downstream mediators such as insulin-like growth factor-1 (IGF-1), keratinocyte growth factor, and enteric nervous system signals, which then act on the epithelium.

The net biological program — described as intestinotrophic — includes:

• Mucosal growth: proliferation of crypt cells, taller villi, and greater absorptive surface area.
• Reduced cell death: less apoptosis in the epithelium, so the lining is maintained.
• Improved barrier and blood flow: enhanced intestinal blood flow and tighter barrier function.
• Slower transit: reduced gastric emptying and gut motility, giving nutrients more contact time to be absorbed.

Together these increase how much nutrient, fluid, and electrolyte the intestine can take up.

Why GLP-2 became a therapeutic target

In short bowel syndrome with intestinal failure (SBS-IF), surgical loss of much of the small intestine leaves too little absorptive surface, so patients often depend on intravenous (parenteral) nutrition. A hormone that literally grows the remaining bowel and boosts its absorption is an almost perfect conceptual fit — enhance the function of what remains and reduce the need for parenteral support.

Native GLP-2 is impractical as a drug because it is degraded within minutes by the enzyme DPP-4 (the same enzyme that inactivates GLP-1). The solution, as with GLP-1, was engineering DPP-4-resistant, longer-acting analogs:

• Teduglutide was the first approved GLP-2 analog, given by daily subcutaneous injection.
• Glepaglutide and apraglutide are longer-acting analogs developed for less frequent (including weekly) dosing, a meaningful convenience gain for a lifelong condition.

Anatomy matters: the colon question

How much a patient benefits from GLP-2 therapy depends partly on their remaining anatomy — in particular whether the colon is still connected in continuity, which influences fluid and electrolyte handling. This is why trials of GLP-2 analogs carefully stratify patients with and without colon-in-continuity, and why treatment is individualized by an intestinal-failure specialist.

The trophic double-edge

The same growth-promoting action that helps a failing gut also means GLP-2 therapy requires monitoring. Because it stimulates cell proliferation, surveillance for intestinal and related changes is part of standard care, and treatment is managed within specialist services rather than self-directed. The lesson is general to trophic peptides: an effect powerful enough to regrow tissue is powerful enough to warrant careful oversight.

Key takeaways

• GLP-2 is co-secreted with GLP-1 from intestinal L-cells but acts on the gut, not on metabolism.
• Through the GLP-2 receptor it drives an intestinotrophic response — more absorptive surface, less epithelial cell death, better barrier and blood flow, and slower transit — largely via mediators like IGF-1.
• This makes GLP-2 an ideal target for short bowel syndrome, where absorptive capacity is the limiting problem.
• DPP-4-resistant analogs (teduglutide, glepaglutide, apraglutide) turn short-lived native GLP-2 into practical medicines, with newer agents aiming for weekly dosing.
• Response depends on remaining bowel anatomy, and the trophic action requires medical monitoring.

This article is educational and does not constitute medical advice. Short bowel syndrome is managed by specialist intestinal-failure teams.